Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26M | 31M |
| Gross Profit | 0 | 0 | 0 | 23M | 29M |
| Operating Income | -39M | -14M | -12M | -43M | -52M |
| EBITDA | -36M | -13M | 19M | -30M | -43M |
| Net Income | -42M | -17M | 19M | -33M | -46M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$113.10
+0.42% today
1Y Change
+401.77%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Palvella Therapeutics, Inc. (PVLA) is a Healthcare stock with a market cap of $1.50B and listed on NASDAQ. The stock last traded around $113.10 and up 401.8% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +52.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +52.6%, free cash flow -130.7% with operating margin 0.0% and ROIC -79.7%. Stock Foundry combines PVLA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PVLA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PVLA Max Drawdown
-31.11%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PVLA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$31.4M
+21.3% YoY
FY Net Income
-$45.7M
-37.4% YoY
Free Cash Flow
-$8.6M
+42.0% YoY
Revenue Growth
+0.0%
EPS Growth
+52.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26M | 31M |
| Gross Profit | 0 | 0 | 0 | 23M | 29M |
| Operating Income | -39M | -14M | -12M | -43M | -52M |
| EBITDA | -36M | -13M | 19M | -30M | -43M |
| Net Income | -42M | -17M | 19M | -33M | -46M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 58M | 84M | 7M | 16M | 118M |
| Total Assets | 60M | 88M | 8M | 17M | 154M |
| Total Liabilities | 32M | 26M | 11M | 40M | 103M |
| Shareholder Equity | 28M | 63M | -4M | -23M | 51M |
| Total Debt | 633K | 0 | 0 | 0 | 15M |
| Net Debt | -57M | -84M | -7M | -16M | -103M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8M
+48.4% YoY
Capital Expenditures
949K
Free Cash Flow
9M
+42.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-98.1%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.